A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections.
In: Vaccine Weekly, 2024-06-21, S. 13-13
serialPeriodical
Zugriff:
A clinical trial, NCT06439342, is being conducted by Takeda to evaluate the effectiveness of maribavir in treating cytomegalovirus (CMV) infection in Chinese adults who have undergone hematopoietic stem cell or organ transplantation. The trial aims to assess the safety, tolerability, efficacy, and pharmacokinetics of maribavir, as well as the recurrence rate of CMV infection and the development of resistance to the medication. Participants will receive maribavir for 8 weeks and will visit the study clinic 18 times. The trial is expected to be completed by February 2027, and Takeda plans to share de-identified individual participant data with qualified researchers. [Extracted from the article]
Copyright of Vaccine Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections.
|
---|---|
Zeitschrift: | Vaccine Weekly, 2024-06-21, S. 13-13 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1074-2921 (print) |
Sonstiges: |
|